Cross-Validation for Nonlinear Mixed Effects Models by Colby, Emily & Bair, Eric
ar
X
iv
:1
30
4.
28
28
v1
  [
sta
t.M
E]
  1
0 A
pr
 20
13
Journal of Pharmacokinetics and Pharmacodynamics manuscript No.
(will be inserted by the editor)
Cross-Validation for Nonlinear Mixed Effects Models
Emily Colby · Eric Bair
Received: Nov. 12, 2012 / Accepted: Mar. 10, 2013
Abstract Cross-validation is frequently used for model selection in a variety of ap-
plications. However, it is difficult to apply cross-validation to mixed effects models
(including nonlinear mixed effects models or NLME models) due to the fact that
cross-validation requires “out-of-sample” predictions of the outcome variable, which
cannot be easily calculated when random effects are present. We describe two novel
variants of cross-validation that can be applied to nonlinear mixed effects models.
One variant, where out-of-sample predictions are based on post hoc estimates of the
random effects, can be used to select the overall structural model. Another variant,
where cross-validation seeks to minimize the estimated random effects rather than
the estimated residuals, can be used to select covariates to include in the model. We
show that these methods produce accurate results in a variety of simulated data sets
and apply them to two publicly available population pharmacokinetic data sets.
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1 Introduction
1.1 Overview of Population Pharmacokinetic and Pharmacodynamic Modeling
Population pharmacokinetic and pharmacodynamic (PK/PD) modeling is the char-
acterization of the distribution of probable PK/PD outcomes (parameters, concentra-
tions, responses, etc) in a population of interest. These models consist of fixed and
random effects. The fixed effects describe the relationship between explanatory vari-
ables (such as age, body weight, or gender) and pharmacokinetic outcomes (such as
the concentration of a drug). The random effects quantify variation in PK/PD out-
comes from individual to individual.
Population PK/PD models are hierarchical. There is a model for the individual,
a model for the population, and a model for the residual error. The individual PK
model typically consists of a compartmental model of the curve of drug concentra-
tions over time. The pharmacokinetic compartmental model is similar to a black box
engineering model. Each of the compartments is like a black box, where a system of
differential equations is derived based on the law of conservation of mass (Sandler,
2006). The number of such compartments to include in the model must be determined
based on the data.
The equations for the PK/PD parameters represent the model for the population
in the hierarchy of models. The PK/PD parameters are modeled with regression equa-
tions containing fixed effects, covariates, and random effects (denoted by η’s). The
random effects account for the variability across subjects in the parameters and for
anything left out of the parameter equations (such as a covariate not included). The
vector of random effects (η) is assumed to follow a multivariate normal distribution
with mean 0 and variance-covariance matrix Ω . The matrix Ω may be diagonal, full
block, or block diagonal. The model for the residual error (ε) accounts for any devia-
tion from the model in the data not absorbed by the other random effects. The residual
error model may be specified such that measurements with higher values are given
less importance compared with measurements with smaller values, often referred to
as “weighting”.
Hence, population PK/PD models are non-linear mixed effects (NLME) models.
They are represented by differential equations that may or may not have closed-form
solutions, and are solved either analytically or numerically. The parameters are es-
timated using one of the various algorithms available such as first order conditional
estimation with interaction (FOCEI). See Wang (2007) for a mathematical descrip-
tion of these algorithms.
Once model parameters are estimated using an algorithm such as FOCEI, one
may fix the values of the model estimates and perform a post hoc calculation to obtain
random effect values (η’s) for each subject. Thus, one may fit a model to a subset of
the data and obtain random effect values for the full data set. See Wang (2007) for a
discussion of how these posterior Bayes (post hoc) estimates of the η’s are calculated.
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1.2 Cross-Validation and Nonlinear Mixed Effects Modeling
In general, cross-validation is not frequently used for evaluating nonlinear mixed
effects (NLME) models (Brendel et al, 2007). When cross-validation is applied to
NLME models, it is generally used to evaluate the predictive performance of a model
that was selected using other methods. For example, in Bailey et al (1996), data were
pooled across subjects to fit a model as though the data were obtained from a sin-
gle subject. Subjects were removed one at a time, and the accuracy of the predicted
observations with subsets of the data was assessed. Another approach (Hooker et al,
2008) removed subjects one at a time to estimate model parameters and predicted PK
parameters using the covariate values for the subject removed. The parameters were
compared with the PK parameters obtained using the full data set in order to evaluate
the final model and identify influential individuals. See Mulla et al (2003), Kerbusch
et al (2001), and Rajagopalan and Gastonguay (2003) for additional examples where
cross-validation was used to validate NLME models.
Less frequently cross-validation is used for model selection in NLME modeling.
For example, one may wish to compare a model with a covariate to another model
without the covariate. In Ralph et al (2006), the prediction error of the posterior PK
parameter for each subject was calculated, and a paired t-test was performed to com-
pare the prediction error between a base and full model to assess whether differences
between the models were significant. The full model was only found to be correct
when the effect of the covariate was large.
In several published studies, cross-validation failed to identify covariate effects
that were identified using other methods. As noted earlier, Ralph et al (2006) found
that cross-validation only identified covariate effects when the effect was large. Sim-
ilarly, Zomorodi et al (1998) found that cross-validation tended to favor a base model
(without a covariate) despite the fact that the covariate was found to be signifi-
cant using alternative approaches. Fiset et al (1995) also found that models with
and without covariates tended to produce comparable error rates despite the fact
that likelihood-based approaches favored models that included covariates. Indeed,
Wahlby et al (2001) used a special form of cross-validation where one concentration
data point was chosen for each parameter, which was the point at which the parame-
ter was most sensitive based on partial derivatives. Once again, little difference was
observed between models that included covariates and corresponding models with-
out covariates. Thus, cross-validation can fail to detect covariate effects even when
attention is restricted to a subset of the data that should be most sensitive to model
misspecification.
Despite the fact that cross-validation may fail to detect covariate effects, it has
been successfully used to compare models with structural differences, such as a par-
allel Michaelis-Menten and first-order elimination (MM+FO) model and a Michaelis-
Menten (MM) model (Valodia et al, 2000). This indicates that cross-validation can be
used for model selection in NLME modeling under certain circumstances. Moreover,
the fact that cross-validation often fails to detect covariate effects is not surprising.
When covariate effects are present in an underlying NLME model, a misspecified
model that fails to include a covariate may not significantly decrease the predic-
tive accuracy of the model. This can occur when random effects in the pharmacoki-
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netic parameters can compensate for the missing covariate. Thus, if cross-validation
chooses the model with the lowest out-of-sample prediction error, it may not be able
to determine whether a covariate should be included in the model.
Other methods have been proposed for using cross-validation for model selection
in NLME modeling (Ribbing and Jonsson, 2001; Katsube et al, 2011). However,
these methods rely on estimation of the likelihood function, which is unusual for
cross-validation, and they have not been studied extensively.
Thus, we propose an alternative form of cross-validation for covariate model se-
lection in NLME modeling. Rather than choosing a model which minimizes the out-
of-sample prediction error, we choose a model which minimizes the post hoc esti-
mates of the random effects (η’s). The motivation is that if the η’s are large, this
suggests that there is a large amount of unexplained variation from individual to in-
dividual, which indicates that a covariate may be missing from the model. However,
traditional cross-validation (which minimizes the out-of-sample prediction error) is
still useful for comparing structural models, as we will discuss below.
2 Methods
2.1 Cross-Validation
Cross-validation is a method for evaluating the expected accuracy of a predictive
model. Suppose we have a response variable Y and a predictor variable X and we
seek to estimate Y based on X . Using the observed X’s and Y ’s we may estimate a
function ˆf such that our estimated value of Y (which we call ˆY ) is equal to ˆf (X).
Cross-validation is an estimate of the expected loss function for estimating Y based
on ˆf (X). If we use squared error loss (as is conventional in NLME modeling), then
cross-validation is an estimate of E
[(
Y − ˆf (X))2].
A brief explanation of cross-validation is as follows: First, the data is divided into
K partitions of roughly equal size. For the kth partition, a model is fit to predict Y
based on X using the K − 1 other partitions of the data. (Note that the kth partition
is not used to fit the model.) Then the model is used to predict Y based on X for
the data in the kth partition. This process is repeated for k = 1,2, . . . ,K, and the K
estimates of prediction error are combined. Formally, let ˆf−k be the estimated value
of f when the kth partition is removed, and suppose the indices of the observations
in the kth partition are contained in Kk. Then the cross-validation estimate of the
expected prediction error is equal to
1
n
k
∑
i=1
∑
j∈Ki
(
y j − ˆf−i(x j)
)2
Here n denotes the number of observations in the data set. For a more detailed dis-
cussion of cross-validation, see Hastie et al (2008).
The above procedure is known as k-fold cross-validation. Leave-one-out cross
validation is a special case of k-fold cross-validation where k is equal to the number
of observations in the original data set.
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2.2 Comparing covariate models
In some situations, a researcher may want to compare models with and without co-
variate effects, such as a model with an age effect on clearance versus a model without
an age effect on clearance. This method is designed to detect differences in models
that affect the equations for the parameters.
Consider a data set with subjects i = 1,2, . . . ,n. Each subject has observations
yi j for j = 1,2, . . . , ti (where ti is the number of time points or discrete values of the
independent variable for which there are observations for subject i). The question of
interest is whether or not a fixed effect dPdX for a covariate X should be included
in an equation for a parameter P, having fixed effect tvP and random effect ηP. The
equation for P could have any of the typical forms used in NLME modeling. For
example, one could compare a model with a covariate X
P = tvP∗ (X/mean(X))dPdX ∗ exp(ηP) (1)
to a model having no covariate effect
P = tvP∗ exp(ηP) (2)
If a covariate X has an effect on a parameter P, the unexplained error in P (modeled
by ηP) when X is left out of the model tends to have higher variance. By including
covariate X in the model, we wish to reduce the unexplained error in P, which is rep-
resented by ηP. Therefore, metrics involving ηP are useful for determining whether
a covariate X is needed. Specifically, one can perform cross-validation to compare
the predicted ηP’s when X is included or not included in the model. We propose a
statistic for determining whether a covariate, X , is needed for explaining variability
in a parameter, P, when P is modeled with a random effect ηP. The statistic can be
calculated as follows:
For i = 1 to n:
1. Remove subject i from the data set.
2. Fit a mixed effects model to the subset of the data with subject i removed.
3. Accept all parameter estimates from this model, and freeze the parameters to
those values.
4. Fit the same model to the whole data set, without any major iterations, estimating
only the post hoc values of the random effects. (In NONMEM, use the commands
MAXITER=0, POSTHOC=Y. In NLME, set NITER to 0.)
5. Square the post hoc eta estimate for the subject that was left out for the parameter
of interest
Take the average of the quantity in step 5 over all subjects.
This sequence of steps can also be represented by the equation
CrVη =
1
n
n
∑
i=1
(ηˆPi,−i)2 (3)
where ηˆPi,−i is the post hoc estimate of the random effect for the ith subject for param-
eter P in a model where the ith subject was removed, and n is the number of subjects.
6 Emily Colby, Eric Bair
Note that our method leaves out one subject at a time, rather than one observation at
a time.
In general, one will favor the model with the minimum value of CrVη . However,
to avoid over-fitting, it is common when applying cross-validation to choose the most
parsimonious model (i.e. the model with the fewest covariates) that is within one
standard error (SE) of the model with minimum CrVη (Hastie et al, 2008). We will
follow this convention in all of our subsequent examples. We define SE(CrVη ) as
the sample standard deviation of the squared post hoc etas for the subjects left out
divided by the square root of the number of subjects. The formula for SE(CrVη ) is
given by
SE(CrVη ) =
√
1
n(n− 1)
n
∑
i=1
(xi− x¯i)2 (4)
where
xi = ηˆ2Pi,−i (5)
Alternatively, one may follow the same procedure while removing more than one
subject at a time. For example, one may divide the data into k roughly equally-sized
partitions, fit a model using the data in k− 1 of the partitions, and calculate the post
hoc η values for the subjects left out of the model. For data sets with large numbers
of subjects, this approach is obviously faster than the “leave-one-out” approach, and
it may also reduce the amount of variance in the cross-validation estimates (Hastie
et al, 2008). However, this approach may not be practical if the number of subjects is
small. We will only consider the leave-one-out method in our subsequent analysis.
2.3 Comparing models with major structural differences
In other situations, a researcher may want to compare models with major structural
differences, such as a one compartment model and a two compartment model. This
method is designed to detect differences in models that affect the overall shape of the
response.
As discussed previously, consider a data set with subjects i = 1,2, . . . ,n, where
each subject has observations yi j for j = 1,2, . . . , ti. The statistic can be calculated as
follows:
For i = 1 to n:
1. Remove subject i from the data set.
2. Fit a mixed effects model to the subset of the data with subject i removed.
3. Accept all parameter estimates from this model, and freeze the parameters to
those values.
4. Fit the same model to the whole data set, without any major iterations, estimating
only the post hoc values of the random effects. (In NONMEM, use the commands
MAXITER=0, POSTHOC=Y. In NLME, set NITER to 0.)
5. Calculate predicted values for subject i (the subject that was left out). Note that
this estimate uses the post hoc estimate of the random effects for subject i.
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6. Take the average of the squared individual residuals for the subject that was left
out (over all time points or over all values of the independent variable ti)
Take the average of the quantity in step 6 over all subjects.
This sequence of steps can also be represented by the equation
CrVy =
1
n
n
∑
i=1
ti
∑
j=1
(yi j − yˆi j,−i)2
ti
(6)
where yi j is the observed value for the ith subject at the jth time point or independent
variable value and yˆi j,−i is the predicted value for the ith subject at the jth time point
or independent variable value in a model where subject i is left out and post hocs are
obtained. Once again, note that our method leaves out one subject at a time, rather
than one observation at a time.
For purposes of exploration, another statistic that takes into account the weighting
of the response can also be calculated:
wtCrVy =
1
n
n
∑
i=1
ti
∑
j=1
WTIRES2i j,−i
ti
(7)
Here WTIRESi j,−i is the individual weighted residual for subject i at time or indepen-
dent variable value j in a model where subject i is left out and post hocs are obtained,
which is defined to be:
WTIRESi j,−i =
√
wti j,−i(yi j − yˆi j,−i)
σˆ−i
(8)
where wti j,−i is the weight defined by the residual error model (equal to the squared
reciprocal of yˆi j,−i for constant CV error models or 1 for additive error models), and
σˆ2−i is the estimated residual variance.
As discussed previously, we will follow the convention of choosing the most par-
simonious model (defined to the model with the fewest number of compartments)
within one standard error (SE) of the model with the minimum CrVy. The formula
for SE(CrVy) is given by
SE(CrVy) =
√
1
n(n− 1)
n
∑
i=1
(xi− x¯i)2 (9)
where
xi =
ti
∑
j=1
(yi j − yˆi j,−i)2
ti
(10)
and the formula for SE(wtCrVy) is calculated similarly, with
xi =
ti
∑
j=1
WTIRES2i j,−i
ti
(11)
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One may also consider k-fold cross-validation, although we will restrict our attention
to leave-one-out for our subsequent analysis.
This method is similar to existing methods for cross-validation on NLME models.
However, some applications of cross-validation do not use post hoc estimates of the
outcome variable, which is an important difference from our proposed method. Also,
we will show why this method should not be used for comparing covariate models.
2.4 Simulated Data Analysis
Five sets of simulated data were generated to evaluate the performance of our pro-
posed cross-validation methods. In each simulation scenario, two models were com-
pared: a sparser “base model” and a less parsimonious “full model.” The objec-
tive was to determine which of the two possible models was correct using cross-
validation.
A brief description of the five simulation scenarios is given in Table 1. For a more
detailed description of how the simulated data sets were calculated, see Section S1
in Online Resource 1. For simulation scenarios 1-4, 200 simulated data sets were
generated using Pharsight’s Trial Simulator software version 2.2.1. (Only 100 simu-
lated data sets were generated for scenario 5.) For each simulated data set, Pharsight’s
Phoenix NLME (platform version 1.3) was used to fit the appropriate population PK
models (both the base model and the full model) using the Lindstrom-Bates method
(Lindstrom and Bates, 1990). The η shrinkage of each model was calculated and di-
agnostics were performed to verify the convergence of each model. To calculate the
cross-validation statistics for each simulated data set, subjects were removed from the
data set one at a time and the models were recalculated with each subject removed.
Post hoc estimates of the random effects (and corresponding predicted values of y)
were then calculated for the subject that was excluded from the model. The values
of CrVη , CrVy, and wtCrVy were obtained by averaging over each such model. The
simulated data sets, batch files, Phoenix mdl files, and other files used to process the
output are available from the authors by request.
For each simulated data set, the base model was selected if the value of CrVη for
the base model was less than that of the full model. The full model was selected if
the value of CrVη was less than that of the base model plus one standard error (using
the convention that the more parsimonious model is preferable if its cross-validation
error is within one standard error of the cross-validation error of a less parsimonious
model). Similar decision rules were used for CrVy and wtCrVy. The Akaike’s in-
formation criterion (AIC) (Akaike, 1974) and Bayesian information criterion (BIC)
(Schwarz, 1978) were also calculated for the two models for each simulated data
set. The model (base or full) with the smallest AIC/BIC was selected under the two
criteria. For each scenario, the performance of cross-validation was compared to the
performance of AIC/BIC using a two-sample proportion test.
Note: Consistent with the recommendations of Vonesh and Chinchilli (1997), the
BIC was weighted by the number of observations. Although others have suggested
that the BIC should be weighted by the number of subjects(Kass and Raftery, 1995),
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Table 1 Description of the five simulation scenarios
Scen. True Model Base Model Full Model
1 one compartment, no co-
variate effects
one compartment, no co-
variate effects
one compartment, age ef-
fect on clearance
2 one compartment, age ef-
fect on clearance
one compartment, no co-
variate effects
one compartment, age ef-
fect on clearance
3 two compartments, age ef-
fect on clearance
two compartments, no co-
variate effects
two compartments, age ef-
fect on clearance
4 one compartment, body
weight effect on volume,
body weight, age, gender,
and hepatic impairment ef-
fects on clearance
one compartment, body
weight effect on volume,
body weight, age, and gen-
der effects on clearance
one compartment, body
weight effect on volume,
body weight, age, gender,
and hepatic impairment ef-
fects on clearance
5 two compartments, no co-
variate effects
one compartment, no co-
variate effects
two compartments, no co-
variate effects
one recent simulation study found that neither choice of weight consistently outper-
forms the other when applied to mixed models (Gurka, 2006).
2.5 Indomethacin Data Analysis
Pharsights Phoenix NLME (version 1.3) was used to fit models to a previously pub-
lished indomethacin data set (Kwan et al, 1976). The data consists of six subjects
with 11 observations per subject. Each subject was administered a 25 mg dose of
indomethacin intravenously at the beginning of the study, and the concentration of
indomethacin was measured at 11 time points over an eight-hour period.
The concentrations were plotted versus time for each subject (see Figure 1). Based
on the plot, a two compartment IV bolus model with clearance parametrization and a
proportional residual error model was fit to this data set. See Section S3.1 in Online
Resource 1 for a more detailed description of the model. Individual initial estimates
were obtained using the curve stripping method (Gibaldi and Perrier, 1982) with a
WinNonlin Classic model. The averages of the individual PK parameters were used
as initial estimates for the pop PK model. Random effects were added to the PK
parameters for systemic volume and clearance in the form θP∗ exp(ηP), where P is
the parameter of interest. The Phoenix project file used to fit this model is available
from the authors by request.
After fitting the model, a series of diagnostic plots were generated to assess the
validity of the model. (See Section S3.2 in Online Resource 1 for details.) The model
was then compared to a one compartment model based on both CrVy and a likelihood
ratio test (LRT). First, the model was refit without including any random effects on the
PK parameters. (The LRT cannot be used when the random effects are included in this
case since the one compartment model forces the removal of some random effects,
which implies that these random effects have variances of 0. Thus, comparing the two
models would require testing the null hypothesis that a variance is equal to 0, which is
on the boundary of the parameter space, rendering the LRT invalid. See Fitzmaurice
et al (2011) for details.). The LRT was used to test the null hypothesis of no difference
10 Emily Colby, Eric Bair
Fig. 1 Concentration versus time profiles from the indomethacin data set
in the predictive accuracy of the two compartment model versus the one compartment
model. The value of CrVy was also calculated for both models. Finally, the value of
CrVy was calculated for a one compartment and two compartment version of the
original model (with random effects included). See Section S3.1 in Online Resource
1 for a detailed description of the models that were considered.
2.6 Theophylline Data Analysis
Pharsights Phoenix NLME (version 1.3) was used to fit models to a published theo-
phylline data set (Boeckmann et al, 1992). This theophylline data set consists of
twelve subjects with eleven observations per subject. Each subject was administered
a dose of theophylline at the beginning of the study ranging between 3.1 mg/kg and
5.86 mg/kg. The concentration of theophylline was measured at 11 time points per
subject over a 24 hour period. Each subject’s weight was also recorded.
The concentration were plotted versus time for each subject (see Figure 2). Based
on the plot, a one compartment extravascular model with clearance parametrization
and an additive residual error model was fit to this data set. Random effects were
added to the PK parameters for absorption rate, and systemic volume and clearance
in the form θP∗ exp(ηP), where P is the parameter of interest. See Section S3.1 in
Online Resource 1 for a more detailed description of the model. The Phoenix project
file used to fit this model is available from the authors by request.
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Fig. 2 Concentration versus time profiles from the theophylline data set
The LRT and the CrVy statistic were used to compare a model with a time lag
parameter (Tlag) to a model without a Tlag parameter, (with no random effect on the
Tlag parameter). Moreover, the covariate plots for the model with Tlag seemed to
indicate a body weight effect on Ka might be needed (see Figure 3). Thus, the LRT
and the CrVη statistic were used to compare a model with the Tlag parameter and
body weight effect on Ka to the model with the Tlag parameter and no body weight
covariate.
Fig. 3 η versus covariate plots for the theophylline model with Tlag and no weight effect on Ka
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Table 2 Proportion of times model comparison methods were correct out of 200 replicates (and associated
standard error)
True Model Comparison AIC BIC wtCrVy CrVy CrVη
1 Cpt 1 Cpt, Age-Cl 0.885 (0.023) 0.945 (0.016) 0.940 (0.017) 0.965 (0.013) 0.970 (0.012)
1 Cpt, Age-Cl 1 Cpt 0.985 (0.009) 0.930 (0.018) 0.0 (0) 0.0 (0) 0.925 (0.018)
2 Cpt, Age-Cl 2 Cpt 0.975 (0.011) 0.940 (0.017) 0.005 (0.005) 0.010 (0.007) 0.930 (0.018)
1 Cpt, BW-V; 1 Cpt, BW-V; 0.715 (0.032) 0.640 (0.034) 0.015 (0.009) 0.005 (0.0005) 0.970 (0.012)
BW-Cl, G-Cl, BW-Cl, G-Cl,
Age-Cl, HI-Cl Age-Cl
2 Cpt 1 Cpt 1.0 (0)* 1.0 (0)* 1.0 (0)* 1.0 (0)* N/A
Cpt=Compartment, Age-Cl indicates age effect on clearance, BW=Body Weight, V=Volume, G=Gender,
HI=Hepatic Impairment
*Based on 100 replicates
3 Results
3.1 Simulation Results
The results of the simulations are summarized in Table 2. The CrVη statistic was
correct in 97.0 percent of the 200 cases under scenario 1, whereas AIC was correct
in 88.5 percent of cases and BIC was correct in 94.5 percent of cases. It correctly
identified the full model under scenario 2 in 92.5 percent of the 200 cases, whereas
AIC found the correct model in 98.5 percent of cases and BIC found the correct model
in 93 percent of cases. Under scenario 3, CrVη was correct in 93.0 percent of cases,
whereas AIC and BIC were correct in 97.5 and 94.0 percent of cases, respectively.
Under scenario 4, CrVη was correct in 97.0 percent of cases, whereas AIC and BIC
were correct in 71.5 and 64.0 percent of cases, respectively. CrVη was significantly
more likely to identify the correct model than AIC in scenario 1 (p = 0.002) and it
was significantly more likely to identify the correct model than both AIC and BIC in
scenario 4 (p< 0.0001 in both cases). The performance of CrVy and wtCrVy was also
evaluated for scenarios 1-4, but it performed poorly in each case with the exception
of scenario 1. All four applicable methods (AIC, BIC, CrVy, and wtCrVy) correctly
identified the true model under scenario 5 in 100 out of 100 cases.
Some additional information about the distributions of the various test selection
statistics are contained in Tables S1, S2, S3, and S4 in Section S1 in Online Resource
1. In general the mean values of AIC and BIC are lower in the true models (compared
to the misspecified values) and the mean value of CrVη is significantly lower in the
true models. This is not true for CrVy and wtCrVy in scenarios 1-4; both statistics
tend to be smaller for the base model irrespective of which model is correct (which
explains the poor performance of these statistics in scenarios 2-4). It is also note-
worthy that an outlying observation generated an extreme value for wtCrVy for one
simulated data set in scenario 3.
Boxplots of the η shrinkage values for both models under scenarios 1-4 are shown
in Figure S6 in Online Resource 1. (The η shrinkage values were not calculated for
scenario 5 since CrVη was not used in this scenario.) The models converged for
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all simulated data sets with the exception of two instances of scenario 5 (although
some instances of all five simulated scenarios produced models that showed signs of
numerical instability).
3.2 Indomethacin Example
The final model appeared to fit well based on the diagnostic plots (see Figures S7, S8,
S9 in Online Resource 1). The model coefficients and shrinkage estimates are shown
in Tables S5 and S6 in Online Resource 1.
The LRT favored the two compartment model (with no random effects) over the
corresponding one compartment model (p< 0.0001). The CrVy statistic was in agree-
ment with the LRT, having a value of 0.1419 (SE 0.03393) for the one compartment
model, and 0.0428 (SE 0.01355) for the two compartment model. The CrVy statistic
in the model with random effects also favored the full (two compartment) model over
the base (one compartment) model. The value of CrVy for the full model was 0.01679
(SE 0.004194) and 0.1406 (SE 0.03358) for the base model.
3.3 Theophylline Example
The final model appeared to fit well based on the diagnostic plots (see Figures S10,
S11, S12 in Online Resource 1). The model coefficients and shrinkage estimates are
shown in Tables S7 and S8 in Online Resource 1.
The LRT favored the Tlag model (p < 0.0001). The CrVy statistic was in agree-
ment with the LRT, having a value of 0.2546 (SE 0.05727) for the model with Tlag,
and 0.3927 (SE 0.10001) for the model without Tlag. The LRT had a borderline result
(p = 0.0667) for comparing the model with a body weight effect on Ka and Tlag to
the model without a body weight effect on Ka and Tlag, while the η versus covariate
plot (Fig 3) indicated an effect. The CrVη statistic clearly favored the full model with
a Tlag and a weight effect on Ka, having a value of 0.06220 (SE 0.02942) for the full
(Tlag and wt) model, and 0.7819 (SE 0.2846) for the base (Tlag) model.
4 Discussion
As noted earlier, cross-validation is not frequently used for comparing NLME mod-
els (Brendel et al, 2007). Other methods, such as the LRT, AIC, and BIC are more
commonly used. However, each of these alternative approaches have certain draw-
backs. All three methods can only be applied to models having the same residual
error model. The LRT can only be applied when models are nested and both models
have the same random effects. Moreover, there may be an inflated type I error rate
associated with the LRTs (Bertrand et al, 2009). Both the AIC and BIC have other
shortcomings as well. Specifically, the AIC tends to overfit, meaning that it keeps too
many covariates in the model. The BIC, in contrast, tends to underfit (fail to include
significant covariates), particularly when the same size is small (Hastie et al, 2008).
14 Emily Colby, Eric Bair
Our results show that cross-validation can be used for model selection in NLME
modeling and that it can produce significantly better results than these competing
methods. The CrVη statistic identified the correct model at least 92.5% of the time in
each of the simulated examples we considered. In contrast, the AIC was significantly
more likely to select a covariate for age in our first simulation scenario (even though
age had no effect on clearance in the simulated model), and both the AIC and BIC
were significantly less likely to detect the effect of hepatic impairment in our fourth
simulation scenario.
All four applicable methods (AIC, BIC, CrVy, and wtCrVy) correctly identified
the true (two compartment) in our fifth simulation scenario in 100 out of 100 cases.
This finding is of interest because the standard likelihood ratio test cannot be applied
when there are random effects in the full model that are not present in the base model.
Both the CrVy statistic and the LRT favored a two compartment model in the in-
domethacin example. However, in the theophylline example, the population covariate
plots (η’s versus covariates) seemed to suggest a weight covariate should be included
in the model even though the LRT was not significant at the p< 0.05 level. The CrVη
statistic clearly favored the model with the weight covariate. This is consistent with
previous studies showing that theophylline distributes poorly into body fat. Hence,
the administered mg/kg dose should be calculated on the basis of ideal body weight,
(Gal et al, 1978; Rohrbaugh et al, 1982) implying that body weight affects the extent
of absorption. This is possible evidence that the LRT cannot always identify covari-
ate effects when they exist and that cross-validation may be able to detect covariate
effects in these situations.
Although it may seem reasonable to use the CrVy or wtCrVy statistics to deter-
mine if a covariate should be included in a model, our simulations suggest that they
can give misleading results. Both statistics consistently favored models without a co-
variate even when a covariate effect existed. The predicted values are just as accurate
with and without the covariate effect when the true model has a covariate effect, be-
cause the η’s can compensate for a missing covariate in a parameter. This suggests
that one should use CrVη rather than CrVy or wtCrVy in situations when one wishes
to compare different covariate models. This also indicates that it may be misleading
to use cross-validation for model validation (as opposed to model selection) if one
uses post hoc estimates of the η’s when calculating the predicted value of the re-
sponse on the “left out” portion of the data. One may obtain a low cross-validation
error rate even when the model is misspecified.
One possible drawback to using cross-validation for model selection is the fact
that it is more computationally intensive than the LRT, AIC, or BIC. Leave-one-out
cross-validation was applied in each of the examples in the present study, since each
example consisted of relatively small data sets. However, larger data sets may require
1-2 hours (or as many as 10 hours in extreme cases), to fit a single model. If such a
data set included hundreds of subjects, leave-one-out cross-validation would clearly
be computationally intractible. In such situations, one may reduce the computing time
by reducing the number of cross-validation folds. If 10-fold cross-validation is per-
formed, this requires that the model be fitted only 10 times, and the number of folds
could be reduced further if needed. Even a complicated model that required ten hours
to fit could be evaluated over the course of several days using 5-fold cross-validation.
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Indeed, these cross-validation methods are no more computationally intensive than
bootstrapping, which is commonly used to validate NLME models. The extra com-
putational cost may be worthwhile in situations where it is important that the model
is specified correctly.
Another potential issue with cross-validation is the fact that estimation methods
for NLME models sometimes fail to converge. Although this was not a major issue
in the examples we considered, if the model fails to converge for a significant propor-
tion of the cross-validation folds, it is possible that it will produce inaccurate results.
Further research is needed on the effects of lack of convergence on our proposed
cross-validation methods.
These methods might be applied more generally with modifications to other types
of linear mixed effects models or generalized linear mixed effects models. These
methods may be applied without modification to population PK/PD models and sparser
data. These are areas for future research. We expect in the sparse data case that the
effectiveness of the covariate selection method may be compromised by η shrinkage,
which could distort the η size criterion. The covariate selection method introduced
in this paper may not produce correct results for parameters with high η shrink-
age (greater than 0.3, for example, in a model where the covariate is not included).
The random effects for those parameters are typically removed during model devel-
opment, and hence covariate adjustments may not be needed for those parameters.
However, cross-validation produced correct results in our first simulation scenario
even though the median shrinkage was approximately 0.3 in the base model (Figure
S6 in Online Resource 1). The conditions under which our proposed cross-validation
method produces valid results in sparse data sets is another area for future research.
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S1 Simulation Details
S1.1 Notation
In the subsequent examples, we denote the following population PK parameters with
the following symbols:
– C: concentration of the drug in central compartment
– C2: concentration of the drug in peripheral compartment
– CObs: observed concentration of the drug (which is measured with error)
– Cε : error associated with CObs
– Aa: amount of the drug in the absorption compartment
– A1: amount of the drug in the central compartment
– A2: amount of the drug in the peripheral compartment
– Ka: absorption rate parameter
– V : systemic volume parameter
– V2: volume of peripheral compartment parameter
– Cl: systemic clearance parameter
– Cl2: clearance of distribution parameter
When any of the parameters above is preceded by tv (i.e. tvKa), this represents a fixed
effect (which is fixed for a given simulation but may vary across the replicates of the
simulated data sets), and when a variable is preceded by η (i.e. ηKa), this represents
a random effect (which varies from subject to subject within a given simulated data
set).
S1.2 Simulation Example 1: No Covariate Effects
A one-compartment, extravascular model was simulated with eight subjects using
Pharsight’s Trial Simulator software (version 2.2.1). The equations for the model are
as follows:
dAa
dt =−Ka ·Aa
dA1
dt = Ka ·Aa−Cl ·C
C = A1
V
A 10 percent constant CV percentage was simulated for the residual error:
CObs =C(1+Cε)
where Var(Cε) = 0.01.
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The absorption rate parameter, Ka, was simulated with only a fixed effect. All
other parameters were simulated with fixed and random effects as follows:
Ka = tvKa
V = tvV · exp(ηV )
Cl = tvCl · exp(ηCl)
The fixed effects for the PK parameters were assumed to be normally distributed
at the study level (varying across replicates) with means listed below and standard
deviations of 0.1:
mean(tvKa) = 0.35
mean(tvV ) = 13.5
mean(tvCl) = 7.4
The random effects (ηV and ηCl) were simulated to be independent and normally
distributed at the subject level (varying across subjects) with means of 0 and variances
of 0.01.
A covariate GENDER was simulated, so that there were 50 percent males and 50
percent females. A covariate BODYWEIGHT was simulated with a mean of 70 kg for
males, 65 kg for females and a standard deviation of 15 for both groups. A covariate
Age was simulated, with a mean of 40 years and a standard deviation of 10. None of
the covariates had any association with the parameters, so the true underlying model
had no covariate effects.
A dose of 5617 was administered at time 0 as an extravascular dose. Two hundred
replicates were simulated. See Figure S1 for a plot of the simulated data.
Pharsights Phoenix NLME software (version 1.3) was used to fit two models to
the simulated data. The base model was a one compartment extravascular model with
random effects for V and Cl and no age effect on clearance. The full model was a one
compartment extravascular model with random effects for V and Cl and an age effect
on clearance. The models are specified below.
Base (correct) model:
Ka = tvKa
V = tvV · exp(ηV )
Cl = tvCl · exp(ηCl)
Full (incorrect) model
Ka = tvKa
V = tvV · exp(ηV )
Cl = tvCl · (Age/40)dCldAge · exp(ηCl)
where tvKa, tvV , tvCl, and dCldAge are fixed effect parameters to be estimated.
Initial estimates for the fixed effect PK parameters (tvKa, tvV , and tvCl) were set
to the true (simulated) parameter values. The initial estimate for the covariate effect
(dCldAge) was set to -3. The initial estimates of the variances of the random effects
were all 0.1, close to the true value of 0.01.
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Fig. S1 Data simulated from a one compartment model with no covariate effects
S1.3 Simulation Example 2: Covariate Effect
A one-compartment, extravascular model was simulated with eight subjects using
Pharsight’s Trial Simulator software (version 2.2.1). The equations for the model are
as follows:
dAa
dt =−Ka ·Aa
dA1
dt = Ka ·Aa−Cl ·C
C = A1
V
A 10 percent constant CV percentage was simulated for the residual error:
CObs =C(1+Cε)
where Var(Cε) = 0.01. A fixed effect was added to the absorption rate parameter, Ka.
All other parameters were simulated with fixed and random effects. The systemic
clearance was simulated with an age effect.
Ka = tvKa
V = tvV · exp(ηV )
Cl = tvCl · (Age/40)dCldAge · exp(ηCl)
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The fixed effects (tvKa, tvV , tvCl, and dCldAge) were assumed to be normally dis-
tributed at the study level (varying across replicates) with means listed below and
standard deviations of 0.05, 0.1, 0.05, and 0.04, respectively.
mean(tvKa) = 0.35
mean(tvV ) = 13.5
mean(tvCl) = 1.2
mean(dCldAge) =−0.9
The random effects (ηV and ηCl) were simulated to be independent and normally
distributed at the subject level (varying across subjects) with means of 0 and variances
of 0.01.
A covariate GENDER was simulated, so that there were 50 percent males and
50 percent females. A covariate BODYWEIGHT was simulated with a mean of 70
kg for males, 65 kg for females and a standard deviation of 15 for both groups. A
covariate Age was simulated, with a mean of 40 years and a standard deviation of 10.
The true underlying model had a covariate effect, namely an age effect on clearance
(see below)
A dose of 5617 was administered at time 0 as an extravascular dose. Two hun-
dred replicates were simulated. See Figure S2 for a plot of the simulated data, with
clearance decreasing with age.
Fig. S2 Data simulated from one a compartment model with age effect on clearance, by quartiles of age
Pharsights Phoenix NLME software (version 1.3) was used to fit two models to
the simulated data. The base model was a one compartment extravascular model with
random effects on V and Cl and no age effect on clearance. The full model was similar
to the base model, but with an age effect included for Cl. The models are specified
below.
Base (incorrect) model:
Ka = tvKa
V = tvV · exp(ηV )
Cl = tvCl · exp(ηCl)
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Full (correct) model
Ka = tvKa
V = tvV · exp(ηV )
Cl = tvCl · (Age/40)dCldAge · exp(ηCl)
where tvKa, tvV , tvCl, and dCldAge are fixed effects parameters to be estimated.
Initial estimates for the fixed effects parameters (tvKa, tvV , tvCl, and dCldAge) were
set to the true (simulated) parameter values. The initial estimates of the variances of
the random effects were all 0.1, close to the true values of 0.01.
S1.4 Simulation Example 3: Covariate Effect in Two Compartment Model
A two-compartment, extravascular model was simulated with eight subjects using
Pharsight’s Trial Simulator software (version 2.2.1). The equations for the model are
as follows:
dAa
dt =−Ka ·Aa
dA1
dt = Ka ·Aa−Cl ·C−Cl2 · (C−C2)
dA2
dt =Cl2 · (C−C2)
C =
A1
V
C2 = A2
V2
A 10 percent constant CV percentage was simulated for the residual error:
CObs =C(1+Cε)
where Var(Cε) = 0.01.
A fixed effect was added to the absorption rate parameter, Ka. All other parame-
ters were simulated with fixed and random effects. The systemic clearance was sim-
ulated with an age effect.
Ka = tvKa
V = tvV · exp(ηV )
V2 = tvV2 · exp(ηV2)
Cl = tvCl · (Age/40)dCldAge · exp(ηCl)
Cl2 = tvCl2 · exp(ηCl2)
The fixed effects (tvKa, tvV , tvV2, tvCl, tvCl2, and dCldAge) were assumed to be
normally distributed at the study level (varying across replicates) with means listed
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below and standard deviations of 0.05, 0.1, 0.1, 0.05, 0.05, and 0.04, respectively.
mean(tvKa) = 0.35
mean(tvV ) = 13.5
mean(tvV2) = 36
mean(tvCl) = 1.2
mean(tvCl2) = 0.62
mean(dCldAge) =−0.9
The random effects (ηV , ηV 2, ηCl, and ηCl2) were simulated to be independent
and normally distributed at the subject level (varying across subjects) with means of
0 and variances of 0.01.
A covariate GENDER was simulated, so that there were 50 percent males and
50 percent females. A covariate BODYWEIGHT was simulated with a mean of 70
kg for males, 65 kg for females and a standard deviation of 15 for both groups. A
covariate Age was simulated, with a mean of 40 years and a standard deviation of 10.
The true underlying model had a covariate effect, namely an age effect on clearance
(see below).
A dose of 5617 was administered at time 0 as an extravascular dose. Two hun-
dred replicates were simulated. See Figure S3 for a plot of the simulated data, with
clearance decreasing with age.
Fig. S3 Data simulated from a two compartment model with age effect on clearance, by quartiles of age
Pharsights Phoenix NLME software (version 1.3) was used to fit two models to
the simulated data. The base model was a two compartment extravascular model with
random effects on V , V2, Cl, and Cl2 and no age effect on clearance. The full model
was similar to the base model, but with an age effect included for Cl. The models are
specified below.
Base (incorrect) model:
Ka = tvKa
V = tvV · exp(ηV )
V2 = tvV2 · exp(ηV2)
Cl = tvCl · exp(ηCl)
Cl2 = tvCl2 · exp(ηCl2)
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Full (correct) model:
Ka = tvKa
V = tvV · exp(ηV )
V2 = tvV2 · exp(ηV2)
Cl = tvCl · (Age/40)dCldAge · exp(ηCl)
Cl2 = tvCl2 · exp(ηCl2)
where tvKa, tvV , tvV2, tvCl, tvCl2, and dCldAge are fixed effects parameters to be
estimated. Initial estimates for the fixed effects parameters (tvKa, tvV , tvV2, tvCl,
tvCl2, and dCldAge) were set to the true (simulated) parameter values. The initial
estimates of the variances of the random effects were all 0.1, close to the true values
of 0.01.
S1.5 Simulation Example 4: Five Covariate Effects
A one compartment, extravascular model was simulated with eight subjects using
Pharsight’s Trial Simulator software (version 2.2.1). The equations for the model are
as follows:
dAa
dt =−Ka ·Aa
dA1
dt = Ka ·Aa−Cl ·C
C = A1
V
A 10 percent constant CV percentage was simulated for the residual error:
CObs =C(1+Cε)
where Var(Cε) = 0.01.
A fixed effect was added to the absorption rate parameter, Ka. All other param-
eters were simulated with fixed and random effects. The systemic volume was sim-
ulated with a body weight effect. The systemic clearance was simulated with body
weight (BW), age (Age), gender (Gender), and hepatic impairment (HI) effects:
Ka = tvKa
V = tvV · (BW/70)dVdBW · exp(ηV )
Cl = tvCl · (BW/70)dCldBW · (Age/40)dCldAge · (1+ dCldGender)
·(1+ dCldHI∗HI) · exp(ηCl)
The fixed effects (tvKa, tvV , tvCl, dVdBW, dCldBW, dCldAge, dCldGender, and
dCldHI) were assumed to be normally distributed at the study level (varying across
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replicates) with means listed below and standard deviations of 0.05, 0.1, 0.05, 0.1,
0.1, 0.04, 0.05, and 0.05 respectively.
mean(tvKa) = 0.35
mean(tvV ) = 13.5
mean(tvCl) = 1.2
mean(dVdBW) = 1
mean(dCldBW) = 0.75
mean(dCldAge) =−0.9
mean(dCldGender) = 0.1
mean(dCldHI) =−0.2
The random effects (ηV and ηCl) were simulated to be independent and normally
distributed at the subject level (varying across subjects) with means of 0 and variances
of 0.01.
A covariate “Gender” was simulated, so that there were 50 percent males (Gen-
der=1) and 50 percent females (Gender=0). A covariate for body weight “BW” was
simulated with a mean of 70 kg for males, 65 kg for females and a standard deviation
of 15 for both groups. A covariate “Age” was simulated, with a mean of 40 years and
a standard deviation of 10. A covariate for hepatic impairment “HI” was simulated,
with 70 percent not hepatically impaired (HI=0) and 30 percent hepatically impaired
(HI=1). The true underlying model had five covariate effects, namely a body weight
effect on volume, and age, body weight, gender, and hepatic impairment effects on
clearance (see below).
A dose of 5617 was administered at time 0 as an extravascular dose. Two hundred
replicates were simulated. See Figure S4 for a plot of the simulated data.
Fig. S4 Data simulated from a one compartment model with body weight effect on volume, and body
weight, gender, age, and hepatic impairment effects on clearance, by hepatic impairment (0=Not hepati-
cally impaired, 1=Hepatically impaired)
Pharsights Phoenix NLME software (version 1.3) was used to fit two models to
the simulated data. The base model was a one compartment extravascular model with
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random effects on V and Cl, a body weight effect on V , and age, gender, and body
weight effects on Cl. The full model was similar to the base model, but with a hepatic
impairment effect also included for Cl. The models are specified below.
Base (incorrect) model:
Ka = tvKa
V = tvV · (BW/70)dVdBW · exp(ηV )
Cl = tvCl · (BW/70)dCldBW · (Age/40)dCldAge · (1+ dCldGender) · exp(ηCl)
Full (correct) model:
Ka = tvKa
V = tvV · (BW/70)dVdBW · exp(ηV )
Cl = tvCl · (BW/70)dCldBW · (Age/40)dCldAge · (1+ dCldGender)
·(1+ dCldHI∗HI) · exp(ηCl)
where tvKa, tvV , tvCl, dVdBW, dCldBW, dCldAge, dCldGender, and dCldHI are
fixed effects parameters to be estimated. Initial estimates for the fixed effects param-
eters were set to the true (simulated) parameter values. The initial estimates of the
variances of the random effects were all 0.1, close to the true values of 0.01.
S1.6 Simulation Example 5: Two compartment model
A two compartment, extravascular model was simulated with six subjects using Phar-
sight’s Trial Simulator software (version 2.2.1). The equations for the model are as
follows:
dAa
dt =−Ka ·Aa
dA1
dt = Ka ·Aa−Cl ·C−Cl2 · (C−C2)
dA2
dt =Cl2 · (C−C2)
C = A1
V
C2 = A2
V2
A 10 percent constant CV percentage was simulated for the residual error:
CObs =C(1+Cε)
where Var(Cε) = 0.01.
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A fixed effect was added to the absorption rate parameter, Ka. All other parame-
ters were simulated with fixed and random effects:
Ka = tvKa
V = tvV · exp(ηV )
V2 = tvV2 · exp(ηV2)
Cl = tvCl · exp(ηCl)
Cl2 = tvCl2 · exp(ηCl2)
The fixed effects for the PK parameters were assumed to be normally distributed at
the study level (varying across replicates) with means listed below and standard de-
viations of 0.1, except in this example the fixed effect for Ka was simulated with
a standard deviation of 0.05 because when the absorption rate was smaller the por-
tion of the curve for the first compartment became less pronounced in relation to
the portion for the second compartment. Having a smaller standard deviation for Ka
increased the chance that all the simulated profiles would have a characteristic two
compartment shape.
mean(tvKa) = 0.35
mean(tvV ) = 13.5
mean(tvV2) = 34
mean(tvCl) = 7.4
mean(tvCl2) = 1.2
The random effects (ηV , ηV2, ηCl, and ηCl2) were simulated to be normally dis-
tributed at the subject level (varying across subjects) with means of 0 and variances
of 0.01.
A dose of 5617 was administered at time 0 as an extravascular dose. One hundred
replicates were simulated. See Figure S5 for a plot of the simulated data.
Pharsights Phoenix NLME software (version 1.3) was used to fit a base model
with one compartment and a full model with two compartments to the simulated
data. The models are specified below.
Base (incorrect) model
Ka = tvKa
V = tvV · exp(ηV )
Cl = tvCl · exp(ηCl)
Full (correct) model
Ka = tvKa
V = tvV · exp(ηV )
V2 = tvV2 · exp(ηV2)
Cl = tvCl · exp(ηCl)
Cl2 = tvCl2 · exp(ηCl2)
where tvKa, tvV , tvV2, tvCl, and tvCl2 are fixed effects parameters to be estimated.
Initial estimates for the fixed effects parameters (tvKa, tvV , tvV2, tvCl, and tvCl2)
were set to the true (simulated) parameter values. The initial estimates of the vari-
ances of the random effects were all 0.1, close to the true values of 0.01.
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Fig. S5 Data simulated from a two compartment model with no covariate effects
S2 Distribution of the Selection Statistics and Shrinkage in the Simulated Data
Sets
For each simulated data set, the values of AIC, BIC, CrVη , CrVy, and wtCrVy were
calculated, along with the standard error of each statistic. Tables S1, S2, S3, and S4
show the mean values and standard deviations of both the statistics and the standard
errors over 200 simulations (or 100 simulations in the case of scenario 5). Further-
more, boxplots of the η shrinkage values for each model under scenarios 1-4 are
shown in Figure S6.
Fig. S6 Boxplots of the η shrinkage values for each model under scenarios 1-4
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Table S1 Distribution of AIC and BIC in each simulation scenario
AIC BIC
Scen. Base Model Full Model Base Full Base Full
1 X1 Cpt 1 Cpt, N 200 200 200 200
Age-Cl Mean 384 404 401 424
SD 114 115 114 115
2 1 Cpt X1 Cpt, N 200 200 200 200
Age-Cl Mean 1106 1093 1124 1113
SD 25 25 25 25
3 2 Cpt X2 Cpt, N 200 200 200 200
Age-Cl Mean 1039 1026 1068 1058
SD 27 27 29 29
4 1 Cpt, BW-V; X1 Cpt, BW-V; N 200 200 200 200
BW-Cl, G-Cl, BW-Cl, G-Cl, Mean 1106 1100 1135 1132
Age-Cl Age-Cl, HI-Cl SD 33 32 33 32
5 1 Cpt X2 Cpt N 100 100 100 100
Mean 648 417 664 443
SD 218 26 218 26
Xindicates true model, Cpt=Compartment, Age-Cl indicates age effect on clearance, BW=Body Weight,
V=Volume, G=Gender, HI=Hepatic Impairment
Table S2 Distribution of CrVη in each simulation scenario
CrVη SE(CrVη )
Scen. Base Model Full Model Base Full Base Full
1 X1 Cpt 1 Cpt, N 200 200 200 200
Age-Cl Mean 0.136 0.919 0.022 0.403
SD 0.236 0.920 0.032 0.512
2 1 Cpt, X1 Cpt, N 200 200 200 200
Age-Cl Mean 0.078 0.012 0.031 0.005
SD 0.056 0.010 0.022 0.005
3 2 Cpt X2 Cpt, N 200 200 200 200
Age-Cl Mean 0.144 0.024 0.077 0.020
SD 0.728 0.155 0.453 0.155
4 1 Cpt, BW-V; X1 Cpt, BW-V; N 200 200 200 200
BW-Cl, G-Cl, BW-Cl, G-Cl, Mean 1.700 0.124 0.626 0.081
Age-Cl Age-Cl, HI-Cl SD 2.577 0.281 2.515 0.214
Xindicates true model, Cpt=Compartment, Age-Cl indicates age effect on clearance, BW=Body Weight,
V=Volume, G=Gender, HI=Hepatic Impairment
S3 Additional Details for the Indomethacin Data Example
S3.1 Model for the Indomethacin Data Analysis
In this analysis, we compared the following two compartment IV bolus model
dA1
dt =−Cl ·C−Cl2 · (C−C2)
dA2
dt =Cl2 · (C−C2)
C = A1
V
C2 = A2
V2
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Table S3 Distribution of CrVy in each simulation scenario
CrVy SE(CrVy)
Scen. Base Model Full Model Base Full Base Full
1 X1 Cpt 1 Cpt, N 200 200 200 200
Age-Cl Mean 41.1 46.4 13.3 18.5
SD 58.4 82.0 51.6 73.6
2 1 Cpt X1 Cpt, N 200 200 200 200
Age-Cl Mean 247 254 45.6 47.2
SD 54.0 59.0 24.4 25.5
3 2 Cpt X2 Cpt, N 200 200 200 200
Age-Cl Mean 159 199 28.0 59.9
SD 34.9 171 12.5 160
4 1 Cpt, BW-V; X1 Cpt, BW-V; N 200 200 200 200
BW-Cl, G-Cl, BW-Cl, G-Cl, Mean 323 472 85.1 173
Age-Cl Age-Cl, HI-Cl SD 116 401 72.2 284
5 1 Cpt X2 Cpt N 100 100 100 100
Mean 206.11 30.28 32.32 8.32
SD 90.3 9.60 20.7 5.74
Xindicates true model, Cpt=Compartment, Age-Cl indicates age effect on clearance, BW=Body Weight,
V=Volume, G=Gender, HI=Hepatic Impairment
Table S4 Distribution of wtCrVy in each simulation scenario
wtCrVy SE(wtCrVy)
Scen. Base Model Full Model Base Full Base Full
1 X1 Cpt 1 Cpt, N 200 200 200 200
Age-Cl Mean 1.14 1.20 0.157 0.176
SD 0.303 0.388 0.064 0.154
2 1 Cpt X1 Cpt, N 200 200 200 200
Age-Cl Mean 0.967 1.01 0.144 0.154
SD 0.133 0.130 0.120 0.111
3 2 Cpt X2 Cpt, N 200 200 200 200
Age-Cl Mean 1.0096 1550* 0.154 1550*
SD 0.0995 21700* 0.071 21700*
4 1 Cpt, BW-V; X1 Cpt, BW-V; N 200 200 200 200
BW-Cl, G-Cl, BW-Cl, G-Cl, Mean 1.25 2.78 0.305 1.56
Age-Cl Age-Cl, HI-Cl SD 0.485 11.6 0.432 11.3
5 1 Cpt X2 Cpt N 100 100 100 100
Mean 14.7 1.14 3.09 0.233
SD 10.1 0.143 2.86 0.130
Xindicates true model, Cpt=Compartment, Age-Cl indicates age effect on clearance, BW=Body Weight,
V=Volume, G=Gender, HI=Hepatic Impairment
*One of the replicates (161) had an inflated value for wtCrVy. One subject was significantly younger than
the others, and the effect of age on clearance was estimated to be around -22 instead of the true value of
-0.9 in the model where this subject was left out. Hence the younger subject had inflated residuals.
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to the corresponding one compartment model:
dA1
dt =−Cl ·C
C =
A1
V
In the above equations, we use the same notation that was defined in Section S1.1. A
constant CV percentage was modeled for the residual error in both cases:
CObs =C(1+Cε)
Under the full (two compartment) model, all PK parameters were modeled with fixed
and random effects:
V = tvV · exp(ηV )
V2 = tvV2 · exp(ηV2)
Cl = tvCl · exp(ηCl)
Cl2 = tvCl2 · exp(ηCl2)
where tvKa, tvV , tvV2, tvCl, and tvCl2 are fixed effects parameters to be estimated.
The corresponding base (one compartment) model was similar:
V = tvV · exp(ηV )
Cl = tvCl · exp(ηCl)
The fixed effects for the PK parameters were set to the following initial values.
tvV = 7551
tvV2 = 13531
tvCl = 8368
tvCl2 = 7056
The random effects (ηV , ηV2, ηCl, and ηCl2) were set to have initial variances of
1.
S3.2 Parameter Estimates and Diagnostic Plots for the Indomethacin Data Analysis
The coefficient estimates for the fixed effects of the indomethacin model are shown in
Table S5, and the estimated variance-covariance matrix is shown in Table S6. To as-
sess the model fit, three diagnostic plots were created. Figure S7 shows the predicted
and observed concentrations over time for all six subjects in the data set. Figure S8
shows a plot of the conditional weighted residuals versus the predicted concentra-
tions. Figure S9 shows a scatter plot of the observed concentrations versus the pre-
dicted concentrations. In each case, no obvious problems are visible, suggesting that
the model fit is adequate.
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Table S5 Parameter estimates for the indomethacin model
Parameter Estimate Units Stderr Stderr%
tvV 8898 mL 574.84 6.46
tvV 2 19527.3 mL 3169.70 16.23
tvCl 7905.99 mL/h 608.53 7.70
tvCl2 5252.15 mL/h 768.93 14.64
σ 0.1440 0.02 13.25
σ denotes the estimated residual standard deviation
prefix of ’tv’ denotes fixed effect or typical value
Table S6 Estimated variance/covariance matrix (Ω ) of the random effects for the indomethacin model
ηV ηCl ηV 2 ηCl2
ηV 0.0017
ηCl 0 0.0338
ηV 2 0 0 0.0666
ηCl2 0 0 0 0.1202
Shrinkage 0.7064 0.0329 0.3321 0.0727
S4 Additional Details for the Theophylline Data Example
S4.1 Model for the Theophylline Data Analysis
A one compartment extravascular model with clearance parametrization was fit to
this data set. The equations for the model are as follows:
dAa
dt =−Ka ·Aa
dA1
dt = Ka ·Aa−Cl ·C
C =
A1
V
In the above equations, we use the same notation that was defined in Section S1.1.
The dose to the absorption compartment is delayed by a parameter Tlag. An additive
weighting scheme was modeled for the residual error:
CObs =C+Cε
A fixed effect was added to the time lag parameter, Tlag. All other parameters were
modeled with fixed and random effects:
Ka = tvKa · (wt/mean(wt))dKadwt · exp(ηKa)
V = tvV · exp(ηV )
Cl = tvCl · exp(ηCl)
Tlag = tvTlag
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Fig. S7 Predicted (lines) and observed (dots) concentrations versus time for the indomethacin model
where tvKa, tvV , tvV2, tvCl, and tvCl2 are fixed effects parameters to be estimated,
and wt is the body weight of a subject in kg and mean(wt) is the average of the body
weights in the data set. This full model was compared to two base models. The first
base model did not include a Tlag parameter nor a covariate for weight:
Ka = tvKa · exp(ηKa)
V = tvV · exp(ηV )
Cl = tvCl · exp(ηCl)
The second base model included a Tlag parameter but no covariate for weight:
Ka = tvKa · exp(ηKa)
V = tvV · exp(ηV )
Cl = tvCl · exp(ηCl)
Tlag = tvTlag
The full model included a Tlag parameter and a covariate for weight:
Ka = tvKa · (wt/mean(wt)dKadwt · exp(ηKa)
V = tvV · exp(ηV )
Cl = tvCl · exp(ηCl)
Tlag = tvTlag
18 Emily Colby, Eric Bair
Fig. S8 Conditional weighted residuals versus predicted values for the indomethacin model
Fig. S9 Observed versus individual predicted values for the indomethacin model
The fixed effects for the PK parameters were set to the following initial values:
tvKa = 2
tvV = 1
tvCl = 1
tvT lag = 1
dKadwt = 0
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Table S7 Parameter estimates for the final theophylline model
Parameter Estimate Stderr Stderr%
tvKa 2.63 0.37 13.89
tvV 0.47 0.02 4.36
tvCl 0.04 0.00 8.01
tvT lag 0.16 0.01 9.18
tvdKadwt 3.07 0.76 24.81
σ 0.55 0.04 7.16
σ denotes the estimated residual standard deviation
prefix of ’tv’ denotes fixed effect or typical value
Table S8 Estimated variance/covariance matrix (Ω ) of the random effects for the final theophylline model
ηV ηKa ηCl
ηV 0.0196
ηKa 0 0.5208
ηCl 0 0 0.0698
Shrinkage 0.0728 0.0276 0.0552
The random effects (ηV , ηKa, and ηCl) were set to have initial variances of 1 in a
diagonal variance-covariance matrix.
S4.2 Parameter Estimates and Diagnostic Plots for the Theophylline Data Analysis
The coefficient estimates for the fixed effects of the indomethacin model are shown
in Table S7, and the estimated variance-covariance matrix is shown in Table S8. To
assess the model fit, three diagnostic plots were created. Figure S10 shows the pre-
dicted and observed concentrations over time for all six subjects in the data set. Figure
S11 shows a plot of the conditional weighted residuals versus the predicted concen-
trations. Figure S12 shows a scatter plot of the observed concentrations versus the
predicted concentrations. In each case, no obvious problems are visible, suggesting
that the model fit is adequate.
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Fig. S10 Predicted (lines) and observed (dots) concentrations versus time for the final theophylline model
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Fig. S11 Conditional weighted residuals versus predicted values for the final theophylline model
Fig. S12 Observed versus individual predicted values for the final theophylline model
